ArticleComputers in biology and medicine2026
Natural language processing of biomedical text to map and prioritize protein-disease associations in HFpEF.
Article in Computers in biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
The validation of promising clinical biomarkers, molecular mechanisms, and novel drug targets in cardiovascular disease (CVD) is hindered by a vast and fragmented biomedical literature, which now exceeds 38 million publications indexed in PubMed. To address the central challenge of navigating and synthesizing a huge fragmented biomedical literature base, we applied our validated machine learning-based text-mining algorithm containing natural language processing (NLP) and incorporated this into a ValIdated Text-mining using Advanced Language model (VITAL) as a complementary framework. Using this approach, we analyzed more than 38 million PubMed abstracts and identified over 5.5 million relevant to six major CVD groups. These curated data then enabled a deep-dive case study on heart failure with preserved ejection fraction (HFpEF). Our computational framework systematically queried, quantified, mapped, and prioritized protein-disease associations, confirming established CVD biomarkers, such as BNP, troponin-I, galectin-3, and renin, and revealing novel protein signatures with potential diagnostic and therapeutic relevance. Ischemic heart disease (IHD, heart attacks), cardiomyopathy (CM, leading to heart failure), and cerebrovascular accidents (CVA, strokes and brain hemorrhages) exhibited the highest protein attribution densities and overlap, suggesting shared molecular pathways. Using HFpEF as a focused case study, our framework identified 5124 proteins associated with this condition, 4879 of which were shared across its major comorbidities (aging, type 2 diabetes/obesity, hypertension, and hyperlipidemia). Additionally, 4991 proteins were co-shared across key pathological mechanisms, including inflammation, mitochondrial dysfunction, and fibrosis, implicating convergent biological networks spanning these domains. To further characterize and prioritize these molecular associations, we performed a series of data science-driven analyses involving HFpEF-associated proteins. The top computationally ranked HFpEF protein candidates were the same top ranked proteins in the comorbidity-domains and in the pathology-domains suggesting that these proteins are important drivers with convergent molecular networks underlying HFpEF. Cross-referencing and validating top-ranked computational HFpEF protein candidates with clinical myocardial and extracardiac biopsy data from HFpEF patients and corresponding controls revealed that most of these proteins are predominantly expressed in the liver, pancreas, adipose tissue, and lymph nodes, rather than in cardiac tissue. This finding supports the emerging concept that HFpEF is fundamentally a multisystemic disorder mediated by inter-organ signaling rather than a disease confined to the heart. Our computational study demonstrates the capacity of text mining to annotate, integrate, and prioritize protein-disease relationships from large-scale textual data, thereby providing a complementary framework to traditional omics approaches for biomarker discovery and drug target identification in CVDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.